Estetrol (E4), the first NEST™
Due to perceived safety and health concerns linked to hormone-related therapies, many women continue to avoid treatment for menopause symptoms or contraceptive solutions. Studies also underline the unmet need today for an estrogen with an improved benefit/risk profile. Preclinical and clinical research to date indicate that E4 could address this unmet need.
Estetrol (E4) is the first NEST™ : Native Estrogen with Selective action in Tissues. Because of its unique mode of action, Mithra believes E4 has the potential to transform the Women’s Health Market, providing an improved side effect profile over current estrogens in key areas including oral contraception and menopause.
Today, Mithra is focused on the development of three late-stage E4-based products : Estelle®, a new era in combined oral contraception, PeriNestaTM, the first complete oral treatment for perimenopause and Donesta®, a next generation hormone therapy for VMS in menopause.
Well well well.
How long market can keep sleeping over it???
Till they unwind the shorts in a stealth manner.
Will the long term investors let them do that???
We shall see.
I stand by my analysis of it being a big multibagger and the potential to merge with Mithra in 3-5 years.
This E4 from Mithra should take the market by storm.
MYX Price at posting:
38.0¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)